Name : Human ALCAM/CD166 Protein
Product Source :
Recombinant Human ALCAM/CD166 Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Trp28-Ala526.[Accession | Q13740-1]
Molecular Weight :
The protein has a predicted MW of 82.7 kDa. Due to glycosylation, the protein migrates to 90-115 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per ug by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human ALCAM on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human ALCAM is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human CD6, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human ALCAM, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA (QC Test). ELISA Data Immobilized Human ALCAM, hFc Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-ALCAM Antibody, hFc Tag with the EC50 of 0.3ug/ml determined by ELISA. SPR Data Human ALCAM, hFc Tag captured on CM5 Chip via Protein A can bind Human CD6, His Tag with an affinity constant of 0.53 μM as determined in SPR assay (Biacore T200).
Background :
Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM.
Synonyms :
CD166; ALCAM; MEMD; CD6L; KG-CAM
References & Citations :
(1) Münsterberg J, Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Hamester F, Robador JR, Bauer AT, Schneider SW, Wrage M, Lamszus K, Matschke J, Vashist Y, Uzunoglu G, Steurer S, Horst AK, Oliveira-Ferrer L, Glatzel M, Schinke T, Corbeil D, Pantel K, Maire C, Wikman H. ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro Oncol. 2020 Jul 7;22(7):955-966. doi: 10.1093/neuonc/noaa028. PMID: 32064501; PMCID: PMC7339886.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Latent TGF beta 1/TGFB1 Proteinmanufacturer
Melanotransferrin/CD228 ProteinSource
Popular categories:
UBE2D2
Macrophage-inducible C-type Lectin/CLEC4E